A retrospective analysis of clinical efficacy of ribavirin in adults hospitalized with severe COVID-19.

ABSTRACT:

Introduction

Coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) swept rapidly throughout the world. So far, no therapeutics have yet proven to be effective. Ribavirin was recommended for the treatment of COVID-19 in China because of its in vitro activity. However, evidence supporting its clinical use with good efficacy is still lacking.

Methods

A total of 208 confirmed severe COVID-19 patients who were hospitalized in Wuhan Union West Campus between 1 February 2020 and 10 March 2020 were enrolled in the retrospective study. Patients were divided into two groups based on the use of ribavirin. The primary endpoint was the time to clinical improvement. The secondary endpoints included mortality, survival time, time to thro

SUBMITTER: Gong WJ 

PROVIDER: S-EPMC7894089 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature